SCHEMBL1702809

SCHEMBL1702809

COc1nc2c(-c3ccc(NS(C)(=O)=O)cc3)cc(C(C)(C)C)cc2cc1-c1ccc[nH]c1=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.50
PIP4K2A P48426 4/20 0.36
PIP4K2B P78356 4/20 0.36
PIP4K2C Q8TBX8 1/20 0.36
PIK3CD O00329 1/20 0.35
PIK3CA P42336 1/20 0.35
PIK3CB P42338 1/20 0.35
PIK3CG P48736 1/20 0.35
JAK2 O60674 1/20 0.35
JAK1 P23458 1/20 0.35
TYK2 P29597 1/20 0.35
JAK3 P52333 1/20 0.35
IKBKB O14920 1/20 0.35
CHUK O15111 1/20 0.35
HSP90AA1 P07900 2/20 0.34
HSP90AB1 P08238 1/20 0.34
BRD4 O60885 3/20 0.34
PDPK1 O15530 1/20 0.34
CRBN Q96SW2 1/20 0.33
CREBBP Q92793 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1702728 0.96 CYP3A4 (0.50) CYP3A4PIP4K2APIP4K2BPIP4K2CPIK3CD
SCHEMBL16143948 0.86 CYP3A4 (0.59) CYP3A4PIP4K2APIP4K2BPIP4K2CPIK3CD
SCHEMBL16143915 0.86 CYP3A4 (0.54) CYP3A4PIP4K2APIP4K2BPIP4K2CPIK3CD
SCHEMBL16508271 0.82 CYP3A4 (0.46) CYP3A4PIP4K2APIP4K2BPIP4K2CPIK3CD
SCHEMBL2691334 0.81 CYP3A4 (0.50) CYP3A4PIP4K2APIP4K2BPIP4K2CIKBKB
SCHEMBL1725631 0.79 CYP3A4 (0.46) CYP3A4PIP4K2APIP4K2BPIP4K2CJAK2
SCHEMBL2692862 0.78 CYP3A4 (0.45) CYP3A4PIP4K2APIP4K2BPIP4K2CIKBKB
SCHEMBL12302462 0.78 KIF11 (0.37) CYP3A4JAK2JAK1TYK2JAK3
SCHEMBL13047380 0.78 CYP3A4 (0.38) CYP3A4
SCHEMBL2692591 0.76 CYP3A4 (0.49) CYP3A4PIP4K2APIP4K2BPIP4K2CIKBKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2440528-B1 HETEROCYCLIC ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2014-10-08 EP claimed
EP-2440528-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2012-04-18 EP claimed
WO-2010142656-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2010-12-16 WO claimed
US-20100311760-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS DE VICENTE FIDALGO JAVIER 2010-12-09 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100311760-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS EIF2AK2, XDH, GTF3C4 CYP3A4 50/4885PIP4K2A 2111/4885PIP4K2B 1750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.